Medvet to Distribute Agendia's MammaPrint Test in Australia | GenomeWeb
NEW YORK (GenomeWeb News) - Medvet Science will distribute Agendia’s MammaPrint breast cancer prognosis test to hospitals in Australia, Agendia said today.
 
The Dutch company said its microarray-based test was developed from a 70-gene tumor expression profile that predicts disease outcome, and will be used by physicians to help plan follow-up therapy. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.